Clinical trial
A Dose-Ranging, Phase II, Open Label Study of ATN 161 in Advanced Renal Cell Cancer
NCT00131651 is registered in ClinicalTrials.gov with Attenuon as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Dose-Ranging, Phase II, Open Label Study of ATN 161 in Advanced Renal Cell Cancer
- Lead sponsor
- Attenuon
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- August 31, 2005
- Completion date
- Not reported
- Enrollment
- 36
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.